dc.contributor.author | Mundal, Håkon S. | |
dc.contributor.author | Rønnestad, Arild Erland | |
dc.contributor.author | Klingenberg, Claus Andreas | |
dc.contributor.author | Stensvold, Hans Jørgen | |
dc.contributor.author | Størdal, Ketil | |
dc.date.accessioned | 2022-02-14T13:34:30Z | |
dc.date.available | 2022-02-14T13:34:30Z | |
dc.date.issued | 2021-12-01 | |
dc.description.abstract | OBJECTIVES - We aimed to study whether national and local antibiotic stewardship projects have reduced the antibiotic use in newborns and to monitor potential changes in adverse outcomes.<p>
<p>METHODS - In a nationwide, population-based study from Norway, we included all hospital live births from 34 weeks' gestation (n = 282 046) during 2015 to 2019. The primary outcome was the proportion of newborns treated with antibiotics from 0 to 28 days after birth. The secondary outcomes were the overall duration of antibiotic treatment and by categories: culture-positive sepsis, clinical sepsis, and no sepsis.<p>
<p>RESULTS - A total of 7365 (2.6%) newborns received intravenous antibiotics during the period, with a reduction from 3.1% in 2015 to 2.2% in 2019 (30% decrease; P < .001). Hospitals with antibiotic stewardship projects experienced the largest reduction (48% vs 23%; P < .001). We found a small decrease in the median duration of antibiotic treatment in newborns without sepsis from 2.93 to 2.66 days (P = .011), and geographical variation was reduced during the study period. The overall number of days with antibiotic treatments was reduced by 37% from 2015 to 2019 (119.1 of 1000 vs 75.6 of 1000; P < .001). Sepsis was confirmed by blood culture in 206 newborns (incidence rate: 0.73 cases per 1000 live births). We found no increase in sepsis with treatment onset >72 hours of life, and sepsis-attributable deaths remained at a low level.<p>
<p>CONCLUSIONS - During the study period, a substantial decrease in the proportion of newborns treated with antibiotics was observed together with a decline in treatment duration for newborns without culture-positive sepsis. | en_US |
dc.identifier.citation | Mundal HS, Rønnestad, Klingenberg, Stensvold, Størdal. Antibiotic Use in Term and Near-Term Newborns
. Pediatrics. 2021;148(6) | en_US |
dc.identifier.cristinID | FRIDAID 1975399 | |
dc.identifier.doi | 10.1542/peds.2021-051339 | |
dc.identifier.issn | 0031-4005 | |
dc.identifier.issn | 1098-4275 | |
dc.identifier.uri | https://hdl.handle.net/10037/24047 | |
dc.language.iso | eng | en_US |
dc.publisher | American Academy of Pediatrics | en_US |
dc.relation.journal | Pediatrics | |
dc.rights.accessRights | openAccess | en_US |
dc.rights.holder | Copyright 2021 The Author(s) | en_US |
dc.title | Antibiotic Use in Term and Near-Term Newborns | en_US |
dc.type.version | acceptedVersion | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |